Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05023304 · ClinicalTrials.gov registry record · Phase 4
In Clinic Optometrist Insertion of Dextenza Prior to Cataract Surgery
A Phase 4 study, sponsored by Vance Thompson Vision.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT05023304: Completed Phase 4 study, sponsored by Vance Thompson Vision.
NCT05023304 is a Phase 4 study that has completed, run by Vance Thompson Vision. The registered enrollment target is 30 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05023304, a Phase 4 study, has completed, sponsored by Vance Thompson Vision.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
To evaluate the clinical outcomes with optometrist pre-surgical insertion of DEXTENZA in the clinical office setting in patients undergoing same-day cataract surgery compared to standard of care steroid therapy.
Primary Outcome
Mean anterior chamber cell/flare score measured by Slit Lamp Biomicroscopy evaluation using grading scale of 0 to 4 +. The scale used is called the (Standardization of Uveitis Nomenclature) SUN Working Group Grading Scheme. AC cell grading schema. The SUN Working Group defined their two AC grading schemas around these two findings. Importantly, for all grading schemas discussed in this article, an improvement in inflammation is a two-step decrease in grade. A worsening of inflammation occurs wit
Interventions
- DRUG Dextenza 0.4Mg Ophthalmic Insert
- DRUG Topical prednisolone acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-08-23 |
| Est. Completion | 2022-10-01 |
| Phase | Phase 4 |
What the finished NCT05023304 record still lists
NCT05023304 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which Dextenza 0.4Mg Ophthalmic Insert is the first listed.
NCT05023304 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05023304 about?
NCT05023304 is a clinical study titled "In Clinic Optometrist Insertion of Dextenza Prior to Cataract Surgery". To evaluate the clinical outcomes with optometrist pre-surgical insertion of DEXTENZA in the clinical office setting in patients undergoing same-day cataract surgery compared to standard of care steroid therapy.
What is the current status of trial NCT05023304?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2021-08-23. Estimated completion is 2022-10-01.
What interventions are being tested in trial NCT05023304?
The interventions under investigation include: Dextenza 0.4Mg Ophthalmic Insert (DRUG), Topical prednisolone acetate (DRUG).
Who is sponsoring clinical trial NCT05023304?
This trial is sponsored by Vance Thompson Vision, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05023304's enrollment target sits among peer trials
30 1552nd of 2000 higher than 367 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI